CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine for Stage IVB Lung Cancer AJCC v8
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
See full descriptionAbout the trial for Stage IVB Lung Cancer AJCC v8
Treatment Groups
This trial involves 2 different treatments. CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine will improve 2 primary outcomes and 6 secondary outcomes in patients with Stage IVB Lung Cancer AJCC v8. Measurement will happen over the course of Baseline and after the third vaccine (at approximately 12 weeks).
Patient Q & A Section
What are common treatments for stage ivb lung cancer ajcc v8?
This document shows some variations in the stage IVb treatment options from the last 5 years. Common options include surgery including pneumonectomy and lobe and wedge resection, with concurrent chemotherapy, radiation therapy including 2D- conformal and 3D-volumetric intensity modulated radiation treatment (IMRT), and targeted therapy agents including anti-epidermal growth factor receptor (EGFR) antibodies and tyrosine kinase inhibitors (TKIs). Treatment of stage IVB is multifactorial, and often includes systemic therapy (chemotherapy and targeted therapy) and local therapy (radiation and surgery).
What is stage ivb lung cancer ajcc v8?
Stage IVB is a heterogeneous group of lung cancer, and there is much variation among its subgroups with regard to pathological, clinical and molecular features.
How many people get stage ivb lung cancer ajcc v8 a year in the United States?
Around 3.3 million patients have stage ivb [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) ajcc v8. Most stage ivb lung cancer ajcc v8 cases occur in white people older than 55 years old. In fact, more non-whites with stage ivb lung cancer ajcc v8 are hospitalized for reasons outside their cancer or chemotherapy, compared with whites. Clinicians should have a high index of suspicion and consider the possibility of stage ivb lung cancer ajcc v8 in Caucasian patients with metastatic lung cancer that is suspected of being either newly diagnosed or recurrent.
What causes stage ivb lung cancer ajcc v8?
For cases with stage IVB lung cancer, the current guideline suggests concurrent chemotherapy with a non-carbohydrate antineoplastic agent (NCA) should be considered. The current study indicated that, in patients with a good performance status and limited symptoms, a multimodal strategy with concurrent chemotherapy should be considered. However, concurrent chemotherapy with an NCA is not recommended for patients with a poor performance status.
Can stage ivb lung cancer ajcc v8 be cured?
In the current era of therapy, there is a lack of consensus regarding the role of surgery in early stage lung cancer. Data from a recent study argues that palliative surgery may have value in patients with early stage disease and that survival was similar whether or not surgery were performed.
What are the signs of stage ivb lung cancer ajcc v8?
Stage IV is a period of declining health that progresses to death within 1 year. Symptoms can include loss of appetite, weight loss, tiredness, feeling depressed, persistent cough, night sweats, swelling of face or tongue, hoarseness of voice or difficulty swallowing, and in more advanced disease, the appearance of new skin conditions and anemia can be alarming. However, stage IV disease is often manageable by utilizing standard cancer treatments. The survival statistics for stage IV lung cancer can be significantly improved by early diagnosis and initiating treatment prior to stage IV disease being symptomatic.
Who should consider clinical trials for stage ivb lung cancer ajcc v8?
Patients with stage IVB lung cancer are likely to be symptomatic, which may explain why almost half of these patients were enrolled. Symptomatic patients and those with the least likelihood of survival should be offered clinical trials in light of the current standard of care of chemotherapy and supportive care.
What does cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine usually treat?
We firstly injected the pME2-SOCS-D vaccines into the subcutaneous lymph nodes of tumor-bearing mice and treated the tumor-bearing mice with pME2-SOCS-D vaccine. pME2-SOCS-D could not just induce tumor regression, but also inhibit tumor growth. pME2-SOCS-D vaccine could provide a potential approach for the treatment of breast cancer patients.
How does cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine work?
In patients with advanced lung cancer, yb-1 is an attractive target for vaccine therapy because it is frequently expressed in lung cancer tissue and associated with tumor progression. The pCD/yb1-1/sox2/hdm2 dna vaccine was less toxic and superior to pHC/pCD with regard to overall survival, and was the most potent vaccine regimen in the study. Results from a recent clinical trial indicate that pCD/yb1-1/sox2/hdm2 dna vaccines should be further explored in a clinical setting.
What is the survival rate for stage ivb lung cancer ajcc v8?
Survival rate for stage IVb is still poor (28.4%). But a few patients can still survive longer than 5 years. Patient with EGFR mutation (18.8%) seems more likely to survive longer than those with WT (28.4%). Further studies should be done in terms of identifying biomarkers and defining appropriate treatments for stage IVb lung cancer.
What is the primary cause of stage ivb lung cancer ajcc v8?
The incidence of stage ivb lung cancer cases in our patient series was similar to the reported incidence of stage 0 lung cancer in other Western countries. The primary cause of stage ivb lung cancer ajcc v8 cannot be determined with a reasonable degree of certainty.
How serious can stage ivb lung cancer ajcc v8 be?
Most patients with stage IVB lung cancer are hospitalized within the year of diagnosis. Many patients require additional diagnostic and therapeutic interventions within the first year. Survival is similar to that reported by previous studies with similar numbers of patients and similar patient characteristics.